Pricing
Prices are indicative MRP and may vary by pharmacy. Trend compares against the last recorded price.
All price changes →Oxima Plus
Rx110 mcg+50 mcg • Dry Powder Inhalation Capsule (DPI)
Indications & Uses
Oxima Plus is indicated for:
Dosage Reference
Reference Information Only
Dosages shown are general references from official sources. Always consult your doctor or pharmacist for personalized dosing.
Adults:
Dosage Adults (18 years or older): For oral inhalation only. Should be used at the same time every day, not more than 1 time every 24 hours.Maintenance treatment of COPD: 1 inhalation once daily.Limitations of use: Not indicated for relief of acute bronchospasm or for the treatment of asthma.Geriatric: This can be used at the recommended dose in elderly patients (65 years of age and older).Use in Children & Adolescents: It is not indicated for use in children and adolescents. The safety and efficacy in pediatric patients (aged 17 years and younger) have not been established.Renal impairment: It can be used at the recommended dose in patients with mild to moderate renal impairment. In patients with severe renal impairment or end-stage renal disease requiring dialysis (estimated glomerular filtration rate is below 30 mL/min/1.73 m2), it should be used only if the expected benefit outweighs the potential risk.Hepatic impairment: It can be used at the recommended dose in patients with mild and moderate hepatic impairment. There are no data available for the use of this in patients with severe hepatic impairment, therefore caution should be observed in these patients.
Side Effects
Adverse reactions that have been associated with muscarinic antagonists include cardiovascular effects (atrial arrhythmias and tachycardia), ocular disorders (e.g., blurred vision), urinary retention, gastrointestinal disorders, dry mouth and cough. Adverse reactions that have been associated with β2-agonists include immediate hypersensitivity reactions (urticaria, rash, bronchospasm, edema and angioedema), cardiovascular effects (tachycardia, arrhythmia, palpitations, myocardial ischaemia, hypertension or. hypotension), hypokalemia, hyperglycemia, headache, nervousness, insomnia, muscle spasms, fatigue, malaise and tremor. The most common adverse drug reactions related to the drug product (reported >3% and greater than placebo) were cough and oropharyngeal pain (including throat irritation).
Cautions & Contraindications
Warnings & Precautions
LABA monotherapy increases the risk of serious asthma-related events. Do not initiate in acutely deteriorating COPD or asthma. Do not use to treat acute symptoms. Do not use in combination with additional therapy containing a LABA because of risk of overdose. If paradoxical bronchospasm occurs, discontinue and institute alternative therapy. Use with caution in patients with cardiovascular disorders because of beta-adrenergic stimulation. Use with caution in patients with convulsive disorders, thyrotoxicosis, diabetes mellitus, and ketoacidosis. Worsening of narrow-angle glaucoma may occur. Use with caution in patients with narrow-angle glaucoma and instruct patients to contact a healthcare provider immediately if symptoms occur. Worsening of urinary retention may occur. Use with caution in patients with prostatic hyperplasia or bladder-neck obstruction contact a physician immediately if symptoms occur. Be alert to hypokalemia and hyperglycemia.
Contraindications
It is contraindicated in patients with hypersensitivity to Glycopyrronium or Indacaterol, or to any other component of this combination; Patients with severe hypersensitivity to milk proteins and All LABA are contraindicated in patients with asthma without use of a long-term asthma control medication.